Invitation to the presentation of ALK’s first nine months (Q3) 2025 results on Thursday, 13 November 2025

Group 1 - ALK will publish its results for the first nine months (Q3) of 2025 on 13 November 2025 [1] - An investor and analyst presentation will be held on the same day at 1:30 p.m. CET, featuring comments on the results and future outlook [1] - Key representatives from ALK during the presentation will include Peter Halling (President & CEO), Claus Steensen Sølje (CFO), and Per Plotnikof (VP, Head of IR) [1] Group 2 - The meeting will be available as a live audio webcast and can be replayed on ALK's website [2] - Participants can join the conference call by registering through a provided link, receiving dial-in details via email [3] - The presentation materials will be accessible on ALK's website shortly before the meeting begins [4] Group 3 - ALK-Abelló A/S is a global specialty pharmaceutical company focused on allergy and allergic asthma treatments [6] - The company markets allergy immunotherapy treatments and other related products and services [6] - ALK is headquartered in Hørsholm, Denmark, employs around 2,800 people globally, and is listed on Nasdaq Copenhagen [6]